Summary.-Splenocytes from inbred Wistar rats bearing a syngeneic squamous cell carcinoma (Spl) were fractionated by several techniques to characterize the lymphoid cells cytotoxic to the tumour in vitro. The anti-tumour cytotoxicity is presumably mediated primarily by T lymphocytes because it was greatly reduced by removal of T lymphocytes with heterologous anti-T serum plus complement but not by removal of other cell types. Cytotoxicity could be blocked at the tumour cell but not at the effector cell by sera taken late in tumour growth. Sera taken earlier in tumour growth could induce cytolysis of tumour cells by normal splenocytes but only if the tumour cells were treated with serum and washed before addition of the effector cells. Although splenocytes from normal and tumour-bearing rats were equally effective at lysing antibody-coated target cells it is unlikely that this mechanism is important in vivo as sera from early in tumour growth onwards contained factors (immune complexes?) which inhibited antibody-induced lymphocytolysis.*
Summary.-Splenocytes from inbred Wistar rats bearing a syngeneic squamous cell carcinoma (Spl) were fractionated by several techniques to characterize the lymphoid cells cytotoxic to the tumour in vitro. The anti-tumour cytotoxicity is presumably mediated primarily by T lymphocytes because it was greatly reduced by removal of T lymphocytes with heterologous anti-T serum plus complement but not by removal of other cell types. Cytotoxicity could be blocked at the tumour cell but not at the effector cell by sera taken late in tumour growth. Sera taken earlier in tumour growth could induce cytolysis of tumour cells by normal splenocytes but only if the tumour cells were treated with serum and washed before addition of the effector cells. Although splenocytes from normal and tumour-bearing rats were equally effective at lysing antibody-coated target cells it is unlikely that this mechanism is important in vivo as sera from early in tumour growth onwards contained factors (immune complexes?) which inhibited antibody-induced lymphocytolysis.* MANY humans and animals with progressing tumours have cytotoxic lymphoid cells for the tumour in vitro and this cytotoxicity can often be abrogated by the host's serum (Hellstr6m and Hellstrom, 1969) . The serum factors appear to be tumour-derived antigen, specific antibody, or complexes of tumour antigen and antibody aind they may operate on either the lymphoid or the tumour cell (Hellstr6m and Hellstrom, 1969; Sj6gren et al., 1971; Currie and Basham, 1972;  Robins, 1972, 1973) . In other studies, sera from tumour-bearing animals have been shown to increase cytolysis of tumour cells by lymphoid cells (Pollack et al., 1973; Basham and Currie, 1974) .
A full understanding of the mechanism of serum modulation of lymphocytolysis requiires knowledge not only of the serum factors but of the nature of the cytotoxic lymphoid cell. In this paper, we examine both the cytotoxic lymphoid cells and their modulation by serum factors in rats bearing a syngeneic squamous cell carcinoma.
MATERIALS ANI) METHODS
Rats and tumour.-Inbred Wistar rats wvere inoculated subcutaneously in the medial aspect of the right thigh with 104 syngeneic squamous cell carcinoma cells (Spl) . This tumour is weakly immunogenic in the syngeneic host and has been shown to induce some transplantation resistance in vivo (Baldwin, 1966) . WTe have shown previously that splenic cytotoxicity is detectable from 4 weeks after tumour inoculation until death of the animal after 8-9 weeks tumour growth (Flannery et al., 1973a) . In the local graftversus-host test of T cell function described below, F1 hybrids between this Wistar subline and DA (Agouti) rats were used. * "Lymphocytolysis" is uised in this communmication to meant cytotoxicity by lymphoreticular cells. "Antibody-induced" is ani abbreviation for any activation of such cells by antigen antibody complexes.
Cytotoxicity against syngeneic squamnus cell carcinoma cells.-Cytotoxicity tests were carried out in Falcon microtitre plates (No. 3034, Falcon Plastics Co.) using a modification (Flannery et al., 1973a) of the procedures of Takasugi and Klein (1970) . Spl tumour cells in Medium 199 + 20% foetal calf serum were incubated in the plates at 37°C overnight. Adherent cells were counted by phase contrast microscopy after washing, and wells containing 50-100 cells were used in all tests. Spleen cell suspensions were then added to give a final effector to target cell ratio of 100: 1. Six to 10 replicates of each test and control well were used. Plates were incubated for a further 40-48 h at 37°C. Plates were washed, fixed with methanol and adherent cells counted by light microscopy. Cytotoxicity was calculated as 100(Nc-Nt)/Nc where Ne and Nt are respectively the mean number of surviving tumour cells in wells with spleen cells from either non-tumour-bearing or tumour-bearing rats. In fractionation experiments, cytotoxicity was expressed relative to non-fractionated control cells because preliminary studies showed that fractionation of control cells had little effect on the number of surviving tumour cells.
Spleen cells from Spl tumour-bearing rats were cytotoxic to Spl cells in vitro but not to (i) another Wistar rat tumour (Walker 256 carcinoma), (ii) a mammary tumour of this inbred line, (iii) normal lung histiocytes from syngeneic animals, when compared with control (non-immune) spleen cells (Flannery, 1974) .
Other assays of lyinphoid cell function.
Phytohaemagglutinin (PHA)-induced proliferation of spleen cells was as described by Matthews and Maclaurin (1973) , antibodyinduced cytolysis of chicken erythrocytes (CRBC) was assayed as described by Matthews and Maclaurin (1974) , and direct plaque-forming cells (PFC) to sheep erythrocytes were assayed by the method of Cunningham and Szenberg (1968) .
Cell fractionation technique8
Fractionation of spleen cells on aggregated immunoglobulin (Agg Ig) columns on treatment with iron carbonyl are described elsewhere (Matthews, Rolland and Nairn, 1975 (Perlmann, Perlmann and Miiller-Eberhard, 1973) . In a typical experiment (Matthews et al., 1975) Shellam (1974) , except that 107 instead of 5 x 107 splenocytes were applied to columns containing 0 3 g nylon fibres.
(a) Treatment with a heterologous anti-l' cell serun.-Two outbred rabbits weighing 2-5 kg received at weekly intervals, three intravenous injections of respectively, 2 x 108 rat thymocytes, 6 x 107 nylon-wool-purified lymph node cells, and finally 3 x 108 thymocytes. This regimen was adopted to raise antibodies against peripheral T lymphocytes as well as thymocytes. The rabbits were bled one week after the final injection, sera were pooled, heat inactivated and absorbed once with rat erythrocytes and thrice with bone marrow cells (anti-T serum), or for neutralization, twice with thymocytes and once with nylon-wool-purified lymph node cells.
To remove T lymphocytes from spleen cell suspensions, 107 splenocytes in 0-9 ml Medium 199 (hereafter called " medium ") were incubated for 15 min at 37°C with 01 ml of a 1 in 10 dilution of anti-T cell serum. Guinea-pig complement (0.1 ml) wNas added and after a further 30 min incubation at 37°C, the cells wNere washed tw-ice, counted, and resuspended at a concentration of Trypan Blue-excluding cells w%hich gave an effector: target ratio of 100: 1.
The specificity of the rabbit anti-rat T cell serum studies w%ias confirmed by several criteria. The lytic effect of anti-T serum plus complement on lymphoid cell suspensions from various organs w-as proportional to their reported T cell content. A plateau level of killing was observed only wtith thymocytes, hence the anti-T cell serum was used at the lowest dilution (1/10) giving maximum lysis of thymocytes, i.e. 92%O.
Under these conditions the antiserum killed 50-60% of lymph node cells, 40-60%0 of splenocytes and less than 5%O of bone marrowcells.
In addition, treatment of normal Wistar spleen cells with anti-T cell serum plus complement markedly reduced their ability to generate a graft-versus-host reaction, an accepted T lymphocyte function (Cantor, 1972) , in the popliteal lymph node assay of Ford, Burr and Simonsen (1970) . Brieflv, 107 parental spleen cells were injected into the hind footpads of F1 hybrid rats and the popliteal node weights determined after 7 days. Contralateral footpads were injected w?ith medium alone. Test lymph node weights (means of groups of 3 ± S.D.) after cell treatment with anti-T cell serum plus complement wA,ere significantly lower (20-7 + 3-9 mg) than after treatment with antiserum alone, complement alone, normal serum plus complement or after no treatment (32-6 ± 10-4 mg; P < 001) by the Mann-Whitney test.
(b) EAC' rosette separation. Rat splenocytes were initially purified by centrifugation over a modified Hypaque/ficoll mixture (Parish and Hayward, 1974) for 10 min at 1200 g; the cells at the interface w%ere collected, washed and resuspended at 5 x 106 cells/ml in medium. The methods of coating sheep erythroeytes (E) with antibody (A) and complement (C'), and EAC' rosette formation with rat splenocytes are described elsewhere (Matthews et al., 1975 (Flannery et al., 1973b ).
For pretreatment of effector cells, 250 ,ul of medium or 1/5 diluted serum were incubated for 1 h at 37°C with 2 5 x 105 immune splenocytes. After washing once, the effector cells were added at a ratio of 100: 1 to untreated Spl tumour cells in microplates.
Results wN-ere expressed as the 00 reduction in cytotoxicity for test serum treatment relative to normal serum treatment.
(b) Capacity of tumour-bearer sera to induce cytolysis of tumour cells by normial splenocytes. Plated Spl cells w%-ere incubated for 1 h at 37TC with 10 jul medium or with serum diluted 1/5 or 1/50. After Awashing, normal splenocytes wAere added to give an effector: target ratio of 100: 1 and the assay was continued as usual. Cytotoxicity was expressed relative to control wells containing medium in place of serum.
(c) Serum inhibition of antibody-induced lysis of EB2 target cells by normal splenocytes.-For the 5'Cr release assays (Matthews and Maclaurin, 1974) , the effector spleen cells (2 x 106) in 0 4 ml medium were incubated for 30 min at 37°C wN-ith 50 ,ul of the test serum or medium, before addition of the 5'Cr-labelled EB2 target cells (2 x 104) plus anti-EB2 serum in a volume of 50 ,ul. The final culture dilution of anti-EB2 serum was 1/5000 and 0 serum inhibition of cytotoxicity was calculated from the expression 100(a -b)/(a-c) where a= ct/min released by spleen cells + anti-EB2 + medium, b = ct/min released by spleen cells + anti-EB2 + test serum, c = ct/min released by spleen cells + medium only.
Rat anti-EB2 serum was induced by giving two intraperitoneal injections of 107 EB2 cells, 2 weeks apart and bleeding 1 week after the second injection.
RESULTS

Fffect of various fractionation procedures on cytolysis of syngeneic tumour cells
Iron carbonyl treatment--Treatment of spleen cells fromn tumour-bearing rats with iron carbonyl had little effect on anti-tumour cytotoxicity (Table 1) , implying that phagocytic cells do not play a major role in the killing process. These iron carbonyl-purified cell suspensions had an increased response to PHA (Tablet), indicating effective re- (Shellam, 1974) thus giving an enriched population of T cells. In our hands, nylon wool purification of spleen cells reduced the number of antibody-forming cells (Table II , experiment 1) and increased the proportion of T cells from 50+ 10% to 85+ 5% as determined by C'-dependent lysis with anti-T cell serum; it had little effect on K cell function (Table II , Experiment 1).
Retention of cytotoxicity after passage through nylon wool or Agg Ig columns suggests that the effector cells are T lymphocytes.
Treatment with anti-T serum plus complement.-Antibody-dependent splenocyte cytotoxicity against CRBC was reduced to some extent by pre-treatment of the effector cells with anti-T serum and C' (Table II) ; possibly by inhibition of effector cells by T lymphocyte-anti- detecting antibody-induced lymphocytolysis (Fig. 3) .
Effect of tumour-bearing serum on lymphocytolysis Mechanismn. of serum abrogation of anti-tumour lymphocytolysis.-Pre-treatment of tumour cells with rat serum taken later in tumour growth (after 6 weeks) protects the tumour cells from lysis by cytotoxic splenocytes (Flannery et al., 1973b) . This is illustrated in Fig. 2 , which also shows that pretreatment of the effector cells with " late " serum has little effect on cytotoxicity. It appears that the relevant serum factor is anti-tumour antibody or complexes of this antibody and tumour-derived antigen in antibody excess. Pretreatment of tumour cells with "late" serum never increased cytotoxicity by immune spleen cells. Serum-dependent cytolysis of tumour cells by normal 8plenocytes. Normal and tumour-bearing sera were tested for their capacity to induce cytolysis of tumour cells by normal splenocytes (Fig. 3) (MacLennan, 1972) . In the experiments in Fig. 3 , the tiumour Detection of antigen-antibody complexes in tumour-bearer serum by inhibition of antibody-induced splenocyte killing of target cells. Fig. 4 compares the inhibitory effect of normal or tumourbearer sera on cytolysis of antibodycoated EB2 cells by normal splenocytes in a 5TCr-release assay. All groups of sera from tumour-bearing rats (2, 4, 6 or 8 weeks) were significantly more inhibitory than normal sera (P<0-02, Wilcoxon rank sum test) suggesting increased serum levels of antigenantibody complexes from 2 weeks after tumour inoculation.
1)ISCUSSION
By several in vitro techniques, spleen cell suspensions from tumour-bearing rats were depleted of the various classes of known effector cells. Cytotoxicity was either increased or unaltered by treatment of cytotoxic spleen cells with iron carbonyl or passage through Agg Ig or nylon wool columns, but markedly reduced by treatment with anti-T serum and C'. Further evidence for an effector T cell is that splenocyte fractions depleted in EAC' receptor-bearing cells (i.e. B lymphocytes and phagocytes) were more cytotoxic than fractions enriched in these cells. Thus in the squamous cell carcinoma-bearing rats, the anti-tumour cytotoxicity measured by our in vitro test is mediated primarily by T lymphocytes.
In humans with melanoma (Wybran et W., 1974) and rats with a Gross virus- induced tumour (Shellam, 1974) , in vitro anti-tumour cytotoxicity is mediated by T lymphocytes. In humans with colonic carcinoma (Nind et al., 1975) and mice with Moloney virus-induced tumours (Lamon et al., 1973; Leclerc et al., 1973) there is evidence of both T and non-T effector cells, whilst in human bladder carcinomas non-T cell killing predominated (O'Toole et al., 1974 (Matthews et al., 1975 (Kirchner et al., 1974 (Bonavida, 1974; Todd, Stulting and Berke, 1973) . Because spleen cells from the rats bearing the squamous cell carcinoma were fully capable of killing antibody-coated target cells in an independent system, it would seem that the presumptive late antibody to tumour that blocks T cell cytotoxicity is for some reason unable to activate K cells or facilitate phagocytosis.
Pretreatment of tumour cells with blocking serum taken at 6-8 weeks of tumour growth failed to induce tumour cell lysis by normal splenocytes, although earlier sera (4-6 weeks) did promote such lysis. Basham and Currie (1974) showed similar effects in sarcoma-bearing rats. In our assay, the tumour cells were washed after treatment with serum to remove any potentially inhibitory antigen-antibody complexes before addition of the normal spleen cells. It is well established that unrelated antigenIgG-antibody complexes can inhibit antibody-induced lymphocytolysis (MacLennan, 1972) . Even from 2 weeks of tumour growth, sera from tumourbearers were more effective than from non-tumour-bearers in inhibiting antibody-induced lymphocytolysis, suggesting that there are increased levels of circulating immune complexes from early in tumour growth. It remains to be established that the antigen in these complexes is tumour-derived. Whatever the nature of the circulating immune complexes, their presence would be expected to exclude an effective in vivo role for antibody-induced lymphocytolysis in rejection of the Spl tumour.
Although in certain circumstances, T cell function can be non-specifically inhibited by antigen-antibody complexes (Gorczynski et al., 1975) , it is unlikely that such a non-specific effect can account for serum abrogation of splenic cytotoxicity against Spl tumour cells. Firstly the blocking sera act only at the tumour cell level and secondly, the effector T cells do not bind Agg Ig (which is analogous to antigen-antibody complexes). 
